Study details
Enrolling now
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
Jeffrey S. Schweitzer, MD, PhD
NCT IDNCT06687837ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
8
Study length
about 3.7 years
Ages
45–80
Locations
1 site in MA
About this study
This trial is testing the safety and tolerability of surgically transplanting cells derived from your own skin stem cells into the brain to help treat Parkinson's disease. The transplanted cells will be dopaminergic, meaning they produce dopamine, a chemical that helps control movement.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive autologous dopaminergic cell implantation
PhasePhase 1
Primary goalSafety and Tolerability
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Safety and Tolerability
Secondary: Change in PD medication usage, Change in Parkinson's disease related quality of life, Global impression of change
Body systems
Neurology